2020
A general-purpose Monte Carlo particle transport code based on inverse transform sampling for radiotherapy dose calculation
Liang Y, Muhammad W, Hart GR, Nartowt BJ, Chen ZJ, Yu JB, Roberts KB, Duncan JS, Deng J. A general-purpose Monte Carlo particle transport code based on inverse transform sampling for radiotherapy dose calculation. Scientific Reports 2020, 10: 9808. PMID: 32555530, PMCID: PMC7300009, DOI: 10.1038/s41598-020-66844-7.Peer-Reviewed Original ResearchConceptsPhoton transportBoundary crossing algorithmMonte Carlo particle transport codeMonte Carlo methodTransport simulationsAcceptance-rejection samplingRadiotherapy dose calculationsPhoto-electric effectParticle transport codeEGSnrc simulationsCarlo methodBremsstrahlung eventsInelastic scatteringPair productionRayleigh scatteringThread divergenceMC simulationsTransport codeMC codeHistory schemeParticle transportCrossing algorithmInverseElectron transportSimulation accuracy
2018
Monte Carlo dosimetry modeling of focused kV x‐ray radiotherapy of eye diseases with potential nanoparticle dose enhancement
Yan H, Ma X, Sun W, Mendez S, Stryker S, Starr‐Baier S, Delliturri G, Zhu D, Nath R, Chen Z, Roberts K, MacDonald CA, Liu W. Monte Carlo dosimetry modeling of focused kV x‐ray radiotherapy of eye diseases with potential nanoparticle dose enhancement. Medical Physics 2018, 45: 4720-4733. PMID: 30133705, DOI: 10.1002/mp.13144.Peer-Reviewed Original ResearchMeSH KeywordsBrachytherapyEye DiseasesModels, BiologicalMonte Carlo MethodNanoparticlesRadiation DosageRadiation-Sensitizing AgentsRadiometryRadiotherapy DosageConceptsX-ray beamMC simulation programEye plaque treatmentCentral axis depth doseMC simulationsDose distributionBeam focusingEye Physics plaquesPhantom irradiationDose enhancementEnergy spectrumDepth doseLens modelingDosimetry modelingPhotoelectric absorptionKV rangeKV X-ray beamsBeamEBT3 filmSimulation programEnergy regimeModelingX-ray techniquesHalf maximumMore flexibility
2017
On the use of bolus for pacemaker dose measurement and reduction in radiation therapy
Yan H, Guo F, Zhu D, Stryker S, Trumpore S, Roberts K, Higgins S, Nath R, Chen Z, Liu W. On the use of bolus for pacemaker dose measurement and reduction in radiation therapy. Journal Of Applied Clinical Medical Physics 2017, 19: 125-131. PMID: 29152840, PMCID: PMC5768029, DOI: 10.1002/acm2.12229.Peer-Reviewed Original Research
2016
Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children
Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. JAMA Oncology 2016, 2: 1574-1581. PMID: 27491009, DOI: 10.1001/jamaoncol.2016.2547.Peer-Reviewed Original ResearchConceptsPostoperative radiotherapyOverall survivalMultivariable logistic regressionNational Cancer Data BaseLogistic regressionAdjuvant chemotherapy strategyLow facility volumeNational treatment patternsMultivariable Cox regressionLong-term morbidityYear of diagnosisDay of surgeryKaplan-Meier analysisNational database analysisPoor overall survivalLog-rank testYoung childrenAge 3Adjuvant chemotherapyRadiotherapy patternsRadiotherapy utilizationWorse survivalDistant metastasisMultivariable analysisTreatment patternsACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal Of Clinical Oncology 2016, 39: 535-544. PMID: 27643717, PMCID: PMC7433865, DOI: 10.1097/coc.0000000000000331.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHodgkin DiseaseHumansMaleNeoplasm InvasivenessNeoplasm StagingOutcome Assessment, Health CarePractice Guidelines as TopicRadiotherapy DosageRandomized Controlled Trials as TopicRisk AssessmentSocieties, MedicalSurvival AnalysisUnited StatesConceptsStage IModality therapyHodgkin's lymphomaAppropriateness CriteriaMedical literatureAppropriateness of imagingACR Appropriateness CriteriaRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literatureLess chemotherapyPeer-reviewed journalsLate effectsClinical conditionsRadiation therapyAmerican CollegeExpert opinionClinical scenariosExcellent efficacyGuideline developmentAvailable evidenceACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensity
2012
Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2011
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers
Chen Z, Roberts K, Decker R, Pathare P, Rockwell S, Nath R. The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Physics In Medicine And Biology 2011, 56: 4895-4912. PMID: 21772076, PMCID: PMC3154133, DOI: 10.1088/0031-9155/56/15/016.Peer-Reviewed Original ResearchMeSH KeywordsBrachytherapyCell SurvivalEdemaHumansMaleNeoplasm StagingProstateProstatic NeoplasmsRadioisotopesRadiotherapy DosageTreatment OutcomeConceptsPermanent interstitial brachytherapyProstate edemaProstate cancerEffects of edemaTumor control probabilityImpact of edemaInterstitial brachytherapyCell survivalEarly-stage prostate cancerControl probabilityStage prostate cancerCurrent clinical practiceProstate cancer cellsTumor cell proliferationInterstitial brachytherapy treatmentSublethal damage repairDose variationTumor cell survivalTumor characteristicsTumor controlClinical impactEdemaEdema evolutionClinical practiceProstate gland
2007
On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy
Chen ZJ, Deng J, Roberts K, Nath R. On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2007, 70: 303-310. PMID: 17980500, PMCID: PMC2289996, DOI: 10.1016/j.ijrobp.2007.09.007.Peer-Reviewed Original ResearchConceptsDose reductionProstate brachytherapyDose compensationLarge edemaBiochemical recurrence-free survivalRecurrence-free survivalSignificant dose reductionEffects of edemaSublethal damage repairAdditional irradiationPrescription doseProstate cancerIndividual patientsEdemaEdema evolutionPrescribed doseProstate edemaEffective doseRadiobiologic effectsBrachytherapyDoseProstate implantsDose responseImplants
2006
Potential impact of prostate edema on the dosimetry of permanent seed implants using the new (model CS‐1) seeds
Chen Z, Deng J, Roberts K, Nath R. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new (model CS‐1) seeds. Medical Physics 2006, 33: 968-975. PMID: 16696473, DOI: 10.1118/1.2179170.Peer-Reviewed Original Research
2004
Relation of clinical success in coronary brachytherapy to dose
Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. The American Journal Of Cardiology 2004, 94: 847-852. PMID: 15464663, DOI: 10.1016/j.amjcard.2004.06.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCase-Control StudiesConnecticutCoronary AngiographyCoronary RestenosisCoronary VesselsDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRadiotherapy DosageRetrospective StudiesStatistics as TopicTreatment OutcomeUltrasonography, InterventionalConceptsTreatment failureExternal elastic membraneTreatment successStent restenosisIntravascular ultrasoundAdequate dose deliveryRecurrent restenosisLesion patternsPrimary treatmentCoronary brachytherapyClinical successPatientsDose prescriptionRadiation delivery systemsArteryRestenosisGyDoseBrachytherapyDose thresholdRadiation delivery devicePotential causesDose deliveryIntravascular brachytherapyTreatmentOptimization of dose distributions for bifurcated coronary vessels treated with catheter‐based photon and beta emitters using the simulated annealing algorithm
Yue N, Roberts KB, Son H, Khosravi S, Pfau SE, Nath R. Optimization of dose distributions for bifurcated coronary vessels treated with catheter‐based photon and beta emitters using the simulated annealing algorithm. Medical Physics 2004, 31: 2610-2622. PMID: 15487744, DOI: 10.1118/1.1783533.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAnimalsBeta ParticlesBlood Vessel ProsthesisBrachytherapyCatheterizationCatheters, IndwellingComputer SimulationCoronary RestenosisHumansModels, CardiovascularPhotonsRadiometryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRelative Biological EffectivenessReproducibility of ResultsSensitivity and SpecificityConceptsTreatment schemeCatheter-based delivery systemBetter dose distributionDose distributionDwell positionsPrescription doseCoronary vesselsBranch vesselsBranch treatmentBifurcation angleSatisfactory dose distributionMultiple dwell positionsVesselsOverdosingDelivery systemGeometry of bifurcationsEffects of vessel curvature on dose distributions in catheter-based intravascular brachytherapy for various radionuclides
Yue N, Roberts K, Nath R. Effects of vessel curvature on dose distributions in catheter-based intravascular brachytherapy for various radionuclides. Cardiovascular Revascularization Medicine 2004, 5: 142-150. PMID: 15721850, DOI: 10.1016/j.carrad.2004.08.002.Peer-Reviewed Original Research
2003
Dose distributions in bifurcated coronary vessels treated with catheter‐based photon and beta emitters in intravascular brachytherapy
Yue N, Roberts KB, Pfau SE, Nath R. Dose distributions in bifurcated coronary vessels treated with catheter‐based photon and beta emitters in intravascular brachytherapy. Medical Physics 2003, 30: 1628-1636. PMID: 12906180, DOI: 10.1118/1.1582813.Peer-Reviewed Original Research
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalitiesDosimetric effects of edema in permanent prostate seed implants: a rigorous solution
Chen Z, Yue N, Wang X, Roberts K, Peschel R, Nath R. Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution. International Journal Of Radiation Oncology • Biology • Physics 2000, 47: 1405-1419. PMID: 10889396, DOI: 10.1016/s0360-3016(00)00549-6.Peer-Reviewed Original Research
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds
1996
Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy
Nath R, Roberts K. Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 977-979. PMID: 8960533, DOI: 10.1016/s0360-3016(96)00441-5.Peer-Reviewed Original ResearchMeSH KeywordsAngioplastyBrachytherapyCombined Modality TherapyCoronary DiseaseHumansRadiotherapy DosageRecurrenceSecond solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissions